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Introduction
Benign prostatic hyperplasia (BPH) is a progressive
disease that is commonly associated with bothersome
lower urinary tract symptoms (LUTS) such as uri-
nary frequency, urgency, nocturia, decreased and
intermittent force of stream and the sensation of
incomplete bladder emptying. The term ‘BPH’ actu-
ally refers to a histological condition, namely the
presence of stromal-glandular hyperplasia within the
prostate gland (1). The condition becomes clinically
relevant if and when it is associated with bothersome
LUTS; however, the relationship between BPH and
LUTS is complex, because not all men with histologi-
cal BPH will develop signiﬁcant LUTS, while other
men who do not have histological BPH will develop
LUTS. Benign prostatic enlargement (BPE) is another
component of the LUTS⁄BPH constellation (1).
Reﬂecting the complex relationship between age-
related changes in the prostate, not all men with his-
tological BPH will develop BPE; in addition, not all
men with LUTS will have concomitant BPE, and not
all men with BPE will have bothersome LUTS. The
ﬁnal component of this complex relationship is blad-
der outlet obstruction (BOO). This results from a
pressure gradient at the bladder neck⁄prostatic ure-
thra and may lead to compression of the urethra,
compromised urinary ﬂow and deterioration of the
upper urinary tract with renal failure (1). Yet again,
not all men with BPH⁄BPE and LUTS will have
BOO, and there are causes of BOO other than
BPH⁄BPE (e.g. primary bladder neck sclerosis or a
urethral stricture).
The causes of LUTS are multifactorial, although
BPE secondary to BPH is a major contributing fac-
tor. The prevalence of LUTS in Europe varies with
age, ranging from 14% for men in their fourth dec-
ade of life to > 40% for men in their sixth decade
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SUMMARY
Benign prostatic hyperplasia (BPH) is a complex disease that is progressive in many
men. BPH is commonly associated with bothersome lower urinary tract symptoms;
progressive disease can also result in complications such as acute urinary retention
(AUR) and BPH-related surgery. It is therefore important to identify men at
increased risk of BPH progression to optimise therapy. Several factors are associ-
ated with progression, including age and prostate volume (PV). Serum prostate-
speciﬁc antigen level is closely correlated with PV, making it useful for determining
the risk of BPH progression. Medical therapy is the most frequently used treatment
for BPH. 5-alpha-reductase inhibitors impact the underlying disease and decrease
PV; this results in improved symptoms, urinary ﬂow and quality of life, and a
reduced risk of AUR and BPH-related surgery. Alpha-blockers achieve rapid symp-
tom relief but do not reduce the overall risk of AUR or BPH-related surgery, pre-
sumably because they have no effect on PV. Combination therapy provides greater
and more durable beneﬁts than either monotherapy and is a recommended option
in treatment guidelines. The Combination of Avodart  and Tamsulosin (CombAT)
study is currently evaluating the combination of dutasteride with tamsulosin over
4 years in a population of men at increased risk of BPH progression. A preplanned
2-year analysis has shown sustained symptom improvement with combination ther-
apy, signiﬁcantly greater than with either monotherapy. CombAT is also the ﬁrst
study to show beneﬁt in improving BPH symptoms for combination therapy over
the alpha-blocker, tamsulosin, from 9 months of treatment.
Review Criteria
Information for this article was gathered using the
PubMed database to identify publications on the
epidemiology of BPH, risk factors for BPH
progression and drug treatment options for the
management of BPH. Reference lists of appropriate
articles served to identify additional publications of
interest, and selected relevant abstracts were also
included.
Message for the Clinic
Benign prostatic hyperplasia is a chronic and
complex disease that is progressive in many men.
In those with moderate-to-severe symptoms and
risk factors for disease progression (an enlarged
prostate, an elevated PSA, age > 60 years), 5ARI
monotherapy is a suitable treatment option to
minimise the risk of disease progression. For a
patient with bothersome symptoms, combination
therapy with a 5ARI and an alpha-blocker could be
a suitable treatment option.
doi: 10.1111/j.1742-1241.2008.01785.x
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prevalence of LUTS across Europe (3). Based on an
overall prevalence of LUTS of 30%, approximately
four million men aged > 40 years have LUTS in
the UK alone (2). Furthermore, with elderly people
constituting a greater proportion of the population,
the prevalence of BPH and its impact on medical
practice will increase.
Although bothersome LUTS are commonly the
only determinant for a BPH diagnosis in clinical
practice, simple investigations exist that can be
highly effective in accurately diagnosing LUTS
because of BPH. The European Association of Urol-
ogy (EAU) guidelines recommend a series of initial
evaluations for men with LUTS suggestive of bladder
obstruction; these include taking a clinical history,
using a validated questionnaire to assess symptoms,
conducting a physical examination, creatinine mea-
surement, urinalysis, ﬂow rates, postvoid residual
(PVR) volume and serum prostate-speciﬁc antigen
(PSA) measurement (particularly when a diagnosis of
prostatic carcinoma would affect the decision about
which therapeutic option to use) (4). The initial
evaluations recommended by the American Urologi-
cal Association (AUA) are a clinical history, use of a
validated questionnaire to assess symptoms, a physi-
cal examination, urinalysis and serum PSA measure-
ment (5). A recent study demonstrated a high
correlation between diagnoses using medical history,
serum PSA, digital rectal examination (DRE) and
International Prostate Symptom Score (IPSS) and
those based on a full battery of tests including ultra-
sonography and uroﬂowmetry (6). Hence, initial
investigations using simple diagnostic tools available
in the primary care setting can offer a ﬁrst diagnostic
step in patients with suspected BPH, as well as a
valid strategy to minimise delay in disease manage-
ment and facilitate appropriate referral from primary
to specialised care (6).
Our growing insight into the natural history of
BPH and the physiological effects of medical inter-
ventions is increasing our understanding of how the
tools available to us can guide therapeutic choices
for individual patients. This review discusses current
knowledge of the progressive nature of BPH and
how the risk of BPH progression can be evaluated to
guide therapeutic choices.
BPH progression: deﬁnitions and
prevalence
An expert review of published evidence regarding
BPH as a progressive disease deﬁned progression as
worsening of symptoms, deterioration of urinary
ﬂow rate, increase in prostate volume (PV), and out-
comes such as acute urinary retention (AUR) and
the need for surgery either for AUR or symptoms
(7). Clinical trials have included renal insufﬁciency
and recurrent urinary tract infections as additional
measures of BPH progression, although these out-
comes were rarely observed (8). Both epidemiological
studies and the placebo arms of randomised con-
trolled trials provide strong evidence that BPH is a
progressive condition in many men.
Symptom progression
One of the largest and longest running longitudinal
studies, the Olmsted County study conducted in
the USA, recruited a sample of 2115 men aged
40–79 years. At 92 months’ follow-up, 31% of parti-
cipants reported a ‡ 3-point increase in AUA Symp-
tom Index (AUA-SI; identical to the seven symptom
questions of the IPSS) score and the mean annual
increase in AUA-SI was 0.34 points (9). In the
placebo arm of the Medical Therapy of Prostatic
Symptoms (MTOPS) study the rate of overall clinical
progression (deﬁned as an increase in AUA-SI of ‡ 4
points, AUR, urinary incontinence, renal insufﬁciency
or recurrent urinary tract infection) was 17.4% over
the 4-year duration of the study. About 78% of
progression events took the form of deterioration in
symptoms (8).
Progression to AUR or BPH-related surgery
Although AUR and surgery are less common than
overall symptomatic worsening, they are important
progression events with ﬁnancial, emotional and
health-related consequences. In the Olmsted County
study, the incidence of AUR in men with moderate-
to-severe LUTS increased from 3.0⁄1000 person-years
in those aged 40–49 years to 34.7⁄1000 person-years
in those aged 70–79 years (10). By extrapolating data
from this study, the overall risk of AUR has been
estimated as 23% for an average 60-year-old man if
he survives another 20 years (10). In the MTOPS
study, 12% of progression events were AUR (8).
AUR results in prostatectomy in 24–42% of men in
the UK and USA, and even patients who avoid sur-
gery through a successful trial without catheter are
subsequently at high risk of requiring surgery within
a year (11–13). Furthermore, longitudinal data from
the Veteran’s Affairs study in the USA has demon-
strated that 36% of men with BPH randomised to
watchful waiting switched to invasive therapy within
5 years of enrolment (14).
Which progression events are of most concern
to our patients?
The above data provide convincing evidence that
BPH is a progressive disease in many men and that
Re-use of this article is
permitted in accordance with
the Creative Commons Deed,
Attribution 2.5, which does not
permit commercial exploitation.
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patients. The most common complaint associated
with BPH is bothersome LUTS. However, some
patient surveys have reported that the risk of surgery
is a greater concern for patients than other factors
such as symptoms or even quality of life (15–17). In
a survey of men treated with ﬁnasteride, 93% of
respondents ranked reducing the need for surgery as
very or extremely important and 88% said that
reducing the risk of major urological complications
was very or extremely important, while symptoms
and quality of life were considered less important
(16). Similarly, a survey of men with BPH in ﬁve
European countries (PROBE) (17) found that 58%
(68⁄117) and 56% (153⁄273) of patients were ‘fairly’
or ‘very’ concerned about the risk of developing
AUR and requiring prostate-related surgery, respec-
tively. Halving the risk of requiring surgery was
ranked as a more important drug treatment outcome
than rapid symptom relief by more than three-quar-
ters of men in this study. This highlights the need
for effective communication with patients so that
treatment decisions are driven by an understanding
of what concerns them most.
Identifying men at risk of BPH
progression
It is important for clinicians to determine which
patients are at increased risk of disease progression
in order to optimise therapy and offer a treatment
approach that correlates with patient preferences.
Numerous factors, such as age and PV, have been
linked with the risk of BPH progression events
(10,18,19). Other predictors include reduced urinary
ﬂow, increased symptom score and increased bother,
which drive healthcare-seeking behaviour. Data from
the placebo arm of the MTOPS trial demonstrated
that men with a total PV ‡ 31 ml, PSA ‡ 1.6 ng⁄ml,
Qmax < 10.6 ml⁄s, PVR volume ‡ 39 ml or
age ‡ 62 years at baseline had a signiﬁcantly
increased risk of overall clinical progression of BPH
(20).
Several studies have demonstrated a relationship
between age and markers of BPH progression. In the
Olmsted County study, moderate-to-severe urinary
symptoms were recorded in 13% and 28% of men
aged 40–49 years and > 70 years respectively (21).
An increase in symptom severity with increasing age
has also been reported in Asian men (22). As previ-
ously discussed, the incidence of AUR among men
with moderate-to-severe symptoms in the Olmsted
County study was shown to increase with increasing
age (10). More recently, a study of men (n = 1859)
with symptomatic BPH showed an increase in PV
with increasing age, from a mean of 27.7 ml in men
aged 40–49 years to 52.3 ml in men aged 70–80 years
(23).
Prostate volume is perhaps the most extensively
studied of the risk factors for BPH progression. Men
with a PV of ‡ 30 ml are more likely to suffer mod-
erate-to-severe symptoms (3.5-fold increase),
decreased ﬂow rates (2.5-fold increase), and AUR
(three- to fourfold increase), compared with men
with PV < 30 ml (24). An enlarged prostate is also
predictive of the need for BPH-related surgery
(10,19). Unfortunately, PV estimated by DRE is asso-
ciated with considerable measurement error and can
underestimate measured volume by as much as 55%
(25,26). Transabdominal ultrasound can be used to
assess PV, although there are limitations with this
technique for imaging the prostate compared with
the more invasive transrectal ultrasound (27). How-
ever, extensive data from the placebo arm of the Pro-
scar Long-term Efﬁcacy and Safety Study (PLESS)
have demonstrated that PSA is a strong predictor of
an enlarged prostate, or one that is likely to increase
in size, as well as the risk of developing LUTS, poor
urinary ﬂow, AUR and⁄or BPH-related surgery (19).
Although the precise relationship between PSA and
prostate growth may vary from one individual to
another (23,28), analysis of the data from PLESS
showed that PSA thresholds for detecting a
PV ‡ 30 ml were ‡ 1.3 ng⁄ml, ‡ 1.5 ng⁄ml and
‡ 1.7 ng⁄ml in men with BPH aged 50–59, 60–69
and 70–79 years, respectively (18). This relationship
was conﬁrmed by a retrospective analysis of 1859
Dutch patients in which 89% of those with a
PSA ‡ 1.5 ng⁄ml had a PV > 30 ml (23). Studies
also demonstrate a correlation between PSA and PV
in Asian men (29,30).
Although it is important to note the limitations of
extrapolating these ﬁndings to individual patients,
the data suggest that the correlation between PSA
and PV is close enough for serum PSA to be used to
estimate the degree of prostatic enlargement. Indeed,
PSA alone showed a sensitivity for predicting the
progression of BPH comparable with the use of an
algorithm and the ﬁve-variable model (encompassing
the indices of serum PSA, symptom problems, peak
urinary ﬂow, urinary frequency £ 2 h and hesitancy)
(31). The current EAU guidelines for the manage-
ment of BPH reﬂect this by stating that PSA (as a
proxy parameter for PV) can be used to evaluate the
risks of either requiring surgery or developing AUR
(4).
Serum PSA is easily measured in clinical practice
and can therefore facilitate identiﬁcation of those
men most likely to suffer disease progression in BPH
and to guide therapeutic decisions. Recent studies
1078 BPH as a progressive disease
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score and PVR volume worsening also serve as good
predictors of AUR in men with LUTS suggestive of
BPH (32). Measurement of PVR volume is also rec-
ommended in the EAU guidelines (4), and this can
be done routinely using transabdominal ultrasound.
Medical therapy for BPH: how can we
optimise the management of men
with BPH?
Over the last decade, there has been a considerable
decline in the popularity of surgery to manage symp-
toms associated with BPH, and medical therapy is
now the most frequently used treatment option in
clinical practice (33). Hence, patients with mild or
moderate symptoms can usually be treated in a pri-
mary care setting, with more complicated cases
referred to an urologist for evaluation and manage-
ment (34).
Treatment of LUTS with plant extracts (phytother-
apies) has a long tradition in countries such as
France and Germany, and is also popular in other
parts of the world (4). However, their mode of
action is unclear and the clinical efﬁcacy of these
agents is largely unproven (35). Additional well-
designed clinical studies are therefore needed before
plant extracts can be recommended for the treatment
of LUTS (4). Current EAU guidelines focus on
alpha-blockers and 5-alpha-reductase inhibitors
(5ARIs), as monotherapies or in combination, when
recommending medical therapy for BPH (4).
The role of alpha-blockers
Effects on symptom scores and symptomatic
progression
The EAU guidelines include alpha-blockers as a
treatment option for BPH where LUTS are bother-
some and there is no absolute indication for surgery
(4). They work by inhibiting alpha1-mediated sympa-
thetic stimulation, and hence promote relaxation of
prostatic smooth muscle and the bladder neck; addi-
tional sites of action include the bladder and central
nervous system (36). Alpha-blockers have a rapid
onset of action, with typical improvements in symp-
tom scores of 30–45% after 3 months’ treatment
(37–40). In the MTOPS study, doxazosin reduced
the risk of symptomatic progression (deﬁned as a
four-point increase in AUA-SI) by 45% relative to
placebo (8).
Effects on AUR and BPH-related surgery
Treatment with an alpha-blocker has not been shown
to reduce the overall long-term risk of AUR or BPH-
related surgery (8,41). In the MTOPS study, doxazo-
sin delayed the time to AUR but did not signiﬁcantly
reduce the cumulative incidence at 4 years compared
with placebo. Similarly, doxazosin did not signiﬁ-
cantly reduce the cumulative incidence of invasive
therapy. In the Alfuzosin Long-Term Efﬁcacy and
Safety Study, alfuzosin did not reduce the risk of
AUR compared with placebo; although a trend
towards a lower incidence of BPH-related surgery
was seen in the alfuzosin group, this did not reach
statistical signiﬁcance when compared with the pla-
cebo group (41). A logical explanation for this would
be the observation that, to date, large-scale studies
have not demonstrated a signiﬁcant effect of alpha-
blockers on PV. In fact, the MTOPS study showed
that patients receiving doxazosin experienced a 24%
increase in PV after an average follow-up of
4.5 years, identical to the increase observed in the
placebo group (8).
Interestingly, data from a ‘real-life’ practice study
suggest that men not responding to alfuzosin treat-
ment (IPSS stable or worsening, and bother score
> 3 under treatment) have a greater risk of AUR or
BPH-related surgery. First-line treatment with alfuzo-
sin might therefore help to select patients at risk of
BPH progression and to optimise their management
(32).
Tolerability
The adverse events (AEs) most commonly observed
with alpha-blockers at a signiﬁcantly higher fre-
quency than with placebo are dizziness and postural
hypotension, although there may be differences in
the rates of such events between individual agents
within the class (40). Alfuzosin and tamsulosin are
better tolerated than terazosin and doxazosin, espe-
cially for cardiovascular AEs (40). Studies have dem-
onstrated a higher incidence of abnormal ejaculation
with tamsulosin compared with placebo (42–45).
The role of 5-alpha-reductase inhibitors
Current EAU guidelines for the management of BPH
recommend 5ARIs for the treatment of bothersome
LUTS in men with a PV > 30–40 ml, when there is
no absolute indication for surgery (4). Others have
proposed that 5ARIs should be considered as ﬁrst-
line medical treatment in men with symptomatic,
progressive BPH as indicated by a PV ‡ 30 ml
and⁄or PSA ‡ 1.5 ng⁄ml (46). 5ARIs prevent the
conversion of testosterone to dihydrotestosterone
(DHT), the primary androgen involved in prostate
development (Figure 1). Two 5ARIs are available for
the treatment of BPH, dutasteride and ﬁnasteride,
which differ in their proﬁle of 5AR inhibition. At
therapeutic doses, ﬁnasteride inhibits only the type 2
BPH as a progressive disease 1079
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tor of both 5AR type 1 and type 2. Treatment with
dutasteride results in a greater degree and consis-
tency of DHT suppression compared with ﬁnasteride.
In a study of men with BPH, the mean per cent
decrease in DHT was 94.7 ± 3.3% with 0.5 mg
dutasteride, signiﬁcantly lower (p < 0.001) and with
less variability than the 70.8 ± 18.3% suppression
observed with 5 mg ﬁnasteride (47).
Effects on symptom scores and symptomatic
progression
In the 4-year PLESS study (n = 3040), ﬁnasteride
treatment signiﬁcantly improved symptom scores
(2.6 points vs. 1.0 for placebo; p < 0.001) (18) (Fig-
ure 2). More recently, the MTOPS study showed that
ﬁnasteride reduced the risk of symptomatic progres-
sion (deﬁned as an increase in the AUA-SI ‡ 4
points) by 30% compared with placebo (p = 0.016).
For the composite primary end-point of overall clini-
cal progression (an increase in AUA-SI ‡ 4 points,
AUR, urinary incontinence, renal insufﬁciency or
recurrent urinary tract infection) ﬁnasteride reduced
the risk by 34% relative to placebo (to 2.9 per 100
person-years; p = 0.002) (8).
Pooled data from phase III studies with dutaste-
ride (n = 4325) showed a 4.5-point improvement in
symptoms at 2 years, compared with 2.3 points in
the placebo group (p < 0.001) (48). Signiﬁcant
improvements in symptoms were observed from
6 months in the majority of patients, and from
3 months in some subjects. At the end of a 2-year
open-label extension of these studies, improvements
in symptom scores increased to 6.5 points (p < 0.001
vs. 2 years of dutasteride treatment) (Figure 3).
Indeed, continuous improvement in symptoms was
seen out to 4 years of treatment with dutasteride
(49).
Effects on AUR and BPH-related surgery
In the PLESS study, after 4 years ﬁnasteride reduced
the relative risk of AUR by 57% (7% of men receiv-
ing placebo and 3% of those receiving ﬁnasteride;
p < 0.001) and surgery by 55% (10% of men receiv-
ing placebo and 5% of those treated with ﬁnasteride,
p < 0.001) (18). A signiﬁcant reduction in the risk of
AUR and need for surgery in patients receiving ﬁnas-
teride monotherapy at 4.5 years (p < 0.001 vs. pla-
cebo) was also shown in the MTOPS study (8).
Similarly, dutasteride studies have shown a reduced
relative risk of AUR (57%) and a surgical interven-
tion (48%) compared with placebo at 2 years (both
p < 0.001 vs. placebo); this reduction was main-
tained to 4 years during open-label phases of the
studies (48,49).
The reduced risk of AUR and BPH-related surgery
with 5ARIs is probably mediated through their
effects on PV. In the PLESS study, ﬁnasteride
reduced PV by 18% compared with a 14% increase
with placebo (mean difference 32%; p < 0.001), and
in the MTOPS study a 19% reduction in PV was
observed in patients receiving ﬁnasteride compared
with a 24% increase in those receiving placebo
(8,18). Phase III studies with dutasteride demon-
strated a 26% reduction in PV relative to placebo,
with signiﬁcant reductions observed from 1 month
after treatment initiation. PV reduction continued to
study end-point at 2 years and was sustained for an
additional 2 years in the open-label extension
(48,49).
Figure 1 The role of 5-alpha-reductase (5aR) and
dihydrotestosterone (DHT) in prostate growth
Figure 2 Effect of ﬁnasteride or placebo on symptom
scores (on the Quasi-American Urological Association
Symptom Scale) in the Proscar Long-term Efﬁcacy and
Safety Study. Reproduced from Ref. (18) with permission
from the Massachusetts Medical Society. Values are mean
(±SE) changes from baseline
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5-alpha-reductase inhibitors are generally well toler-
ated; sexual AEs are the most commonly reported
side effects, although it is worth noting that there is
a relatively high prevalence of sexual dysfunction in
untreated men with BPH (50). Furthermore, studies
have shown that the incidence of drug-related sexual
AEs decreases during prolonged treatment (18,51).
In the PLESS study, the rates of decreased libido and
impotence were identical in ﬁnasteride and placebo
groups after 2 years (18). Similarly, during 4 years of
dutasteride treatment there was a trend towards a
reduction in the rate of newly reported sexual AEs
over time (51).
Although 5ARI therapy reduces serum PSA, this
reduction is predictable and more importantly it
does not jeopardise the diagnostic performance of
PSA for detecting prostate cancer. Analyses of BPH
clinical trials have shown that 5ARIs reduce serum
PSA levels by approximately 50–60% after 6 months
treatment. Hence, using doubled PSA values from
6 months onwards in 5ARI-treated men, and estab-
lishing a new baseline PSA level, preserves the clinical
utility of the PSA test in prostate cancer detection
irrespective of PSA level (52,53). Data from the
PCPT show that treatment with ﬁnasteride may have
actually enhanced the sensitivity of PSA for detecting
all prostate cancers and high-grade disease because of
preferential suppression of PSA related to BPH (54).
The role of 5ARI⁄alpha-blocker combination
therapy
It is clear from the available evidence that alpha-
blockers offer rapid symptomatic relief without tar-
geting the underlying disease process, while 5ARIs
provide mid- and long-term symptom relief as well
as a reduction in the risk of progression events such
as AUR and BPH-related surgery. These complemen-
tary effects provide a sound rationale for 5ARI⁄al-
pha-blocker combination therapy, which provides
greater and more durable beneﬁts than either mono-
therapy and is a recommended treatment option in
the EAU guidelines (4).
Initial studies, assessing ﬁnasteride in combination
with terazosin, doxazosin or alfuzosin, failed to
establish a beneﬁt for combination therapy over pla-
cebo or alpha-blocker monotherapy in terms of
improving LUTS or Qmax (55–57). However, these
studies were limited by their short duration
(6 months to 1 year), during which time a signiﬁcant
response to ﬁnasteride therapy was unlikely to occur.
In contrast, the MTOPS study showed that the risk
of long-term clinical progression was reduced by
66% with combination therapy (p < 0.001 vs. pla-
cebo) and to a greater extent than with either ﬁnas-
teride or doxazosin monotherapy (34% and 39%
respectively) (8). All treatments resulted in a signiﬁ-
cant improvement in symptom scores, with combi-
nation therapy proving superior to either doxazosin
(p = 0.006) or ﬁnasteride (p < 0.001) alone. The
risks of AUR and need for BPH-related surgery over
the 4-year study were signiﬁcantly reduced with
combination therapy and ﬁnasteride monotherapy
(both p < 0.001) but not with doxazosin monothera-
py (8). A recent analysis of the MTOPS data con-
cluded that men with PV ‡ 25 ml and a
PSA ‡ 1.5 ng⁄ml may beneﬁt from combination
therapy (58).
A large-scale study is currently examining the
effects of the dual 5ARI dutasteride, both as mono-
therapy and in combination with tamsulosin, on
symptoms and progression of BPH. The Combina-
Figure 3 Mean change in American Urological Association Symptom Index scores from baseline over 48 months.
Reproduced from Ref. (49) with permission from Elsevier. *p < 0.001 between treatment groups; p < 0.001 for
differences for both treatment groups from month 24
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  and Tamsulosin (CombAT) study
is a 4-year, international, multicentre study that dif-
fers from MTOPS in several important respects (59).
While the MTOPS study inclusion criteria were lar-
gely related to symptoms, additional entry thresholds
for PV (‡ 30 ml) and PSA (‡ 1.5 ng⁄ml) in the
CombAT trial have been used to select patients who
are at higher risk of disease progression. Further-
more, the independent assessment of symptom relief
at 2 years and risk of AUR and surgery at 4 years in
the CombAT trial, compared with the composite pri-
mary end-point of clinical progression in the
MTOPS study, will allow a more transparent exami-
nation of which parameter is contributing to the
overall treatment effect. This study therefore allows
the assessment of those patients most likely to beneﬁt
from combination therapy, rather than evaluating
the role of combination therapy across the entire
spectrum of the disease.
A preplanned analysis of CombAT at 2 years has
shown sustained symptom improvement with combi-
nation therapy, and a signiﬁcantly greater degree of
improvement compared with either dutasteride or
tamsulosin monotherapy (60,61). At month 24,
reductions in the IPSS were )6.2 with combination
therapy, )4.9 with dutasteride (p < 0.001 vs. combi-
nation therapy), and )4.3 with tamsulosin
(p < 0.001 vs. combination therapy) (Figure 4). In
addition, CombAT is the ﬁrst study to show beneﬁt
in improving BPH symptoms for combination ther-
apy over monotherapies in the ﬁrst 12 months of
treatment; a signiﬁcant improvement vs. dutasteride
was evident from month 3 and tamsulosin from
month 9 (61). At month 24, the signiﬁcance level in
a post hoc analysis for dutasteride vs. tamsulosin was
p = 0.013. Improvement in quality of life (as assessed
by question 8 of the IPSS) was signiﬁcantly greater
for combination therapy ()1.4) than for either
monotherapy at month 24 (change from baseline for
both )1.1; p < 0.001 for both comparisons) (61). In
addition, Qmax improvements from baseline were sig-
niﬁcantly better with combination therapy than with
either monotherapy at all time points from month 6
to month 24 (each p £ 0.006); at month 24, mean
changes from baseline were +2.4 ml⁄s with combina-
tion therapy, +1.9 ml⁄s with dutasteride and
+0.9 ml⁄s with tamsulosin (61). Overall, a similar
proportion of AEs were reported in each treatment
group. Drug-related AEs were more common with
combination therapy than with either monotherapy
(particularly erectile dysfunction, ejaculatory disor-
ders and decreased libido), although withdrawals due
to AEs were low in all groups (61).
Studies have assessed the discontinuation of
alpha-blocker and continuation of 5ARI therapy in
men with symptomatic BPH receiving combination
therapy (62,63). The results showed that symptom
relief was maintained after alpha-blocker withdrawal
Figure 4 Change in International Prostate Symptom Score following treatment with dutasteride, tamsulosin or
dutasteride⁄tamsulosin in combination. Reproduced from Ref. (60) with permission from Elsevier. *p < 0.001 for
combination vs. dutasteride; p < 0.001 for combination vs. tamsulosin; p = 0.18 for combination vs. tamsulosin;
§p = 0.032 for combination vs. tamsulosin
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toms, whereas those with severe symptoms were
more likely to experience worsening. However, the
studies were of relatively short duration
(9–12 months) and patient numbers were relatively
small. There is now evidence from two large,
randomised studies (MTOPS and CombAT) to
demonstrate the beneﬁts of long-term combination
treatment over monotherapy for improving symp-
toms (8,61).
Discussion and conclusions: how
should the evidence guide treatment
choices in BPH?
Benign prostatic hyperplasia is a chronic, complex
disease that is progressive in many men. Although
symptom deterioration is the most frequently occur-
ring progression event, patients are often more con-
cerned about progression to events such as AUR or
BPH-related surgery. It is interesting to note that the
risk of AUR is comparable with other conditions that
are linked with ageing, such as diabetes, stroke and
myocardial infarction, for which preventative
approaches are commonplace. Given the signiﬁcant
pain, discomfort, economic and emotional burden
associated with AUR and prostate surgery, it is
important to consider therapeutic approaches that
reduce the risk of such progression events while also
achieving symptom relief. This approach responds to
the needs of patients and is endorsed by the current
EAU guidelines. Although alpha-blockers provide
rapid symptom relief that is maintained in the long
term, 5ARIs have been shown to provide continued
symptom improvements (to 4 years with dutasteride)
while also reducing the risk of progression to AUR
or BPH-related surgery.
Men with enlarged prostates (> 30 ml) are at par-
ticularly high risk of disease progression and should
receive the most effective management strategy avail-
able, derived from current guidelines and existing
evidence. Although accurate PV measurement is dif-
ﬁcult using DRE, elevated PSA is an accurate predic-
tor of an enlarged prostate (once prostate cancer has
been ruled out) and it can be used as a helpful tool
to estimate PV. A PSA threshold of ‡ 1.5 ng⁄ml
should be used to identify patients at high risk of
BPH progression. However, serum PSA is also an
important component in the detection of prostate
cancer, and a concentration of > 4 ng⁄ml requires
further evaluation and consideration of prostate
biopsy. Dynamic variables such as symptom scores
and PVR volume may also be helpful in predicting
those men at risk of suffering AUR.
5-alpha-reductase inhibitors are the only therapy
that alter the underlying disease process and prevent
BPH disease progression. Although 5ARIs reduce
serum PSA levels by approximately 50% after
6 months, they do not mask PSA changes; doubling
the PSA measurement in treated men and establish-
ing a new baseline preserves the utility of the test for
detecting prostate cancer. In fact, recent data have
shown that treatment with a 5ARI may enhance the
sensitivity of the PSA test for prostate cancer detec-
tion (53).
A proposed treatment algorithm, based on guide-
line recommendations and published evidence, is
summarised in Figure 5 (64). In men with risk fac-
tors for BPH progression (including PV ‡ 30 ml and
serum PSA ‡ 1.5 ng⁄ml) and an IPSS ‡ 7, 5ARI
monotherapy is a recommended treatment option to
minimise the risk of disease progression. For patients
with an enlarged prostate and moderate-to-severe
bothersome symptoms, who are unable to wait for
Figure 5 Proposed algorithm for medical therapy of benign prostatic hyperplasia. Adapted from Ref. (64) with permission
from Macmillan Publishers Ltd
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can be added to therapy. Ultimately, patients should
be presented with a reasonable estimate of their base-
line risk of progression along with the beneﬁts and
risks of medical therapy and the need for long-term
treatment so that an informed decision can be made.
Efﬁcient and effective allocation of treatment accord-
ing to severity and risk factors will result in fewer
patients being treated with minimal beneﬁts.
The CombAT study is underway to further exam-
ine the role of 5ARI⁄alpha-blocker combination ther-
apy (dutasteride + tamsulosin) compared with
monotherapy in the management of BPH. In com-
parison with the MTOPS study, men recruited into
the CombAT study are deemed to be at higher risk
of BPH progression, with baseline PV ‡ 30 ml and
PSA levels of ‡ 1.5 ng⁄ml. A preplanned interim
analysis of 2-year data from CombAT has shown sus-
tained symptom improvement with combination
therapy, with a greater degree of improvement com-
pared with either dutasteride or tamsulosin mono-
therapy. In addition, CombAT is the ﬁrst study to
show beneﬁt in improving BPH symptoms for com-
bination therapy over the alpha-blocker, tamsulosin,
in the ﬁrst 9 months of treatment. The CombAT
study represents the next major step in assessing the
overall value of combination therapy in men with
symptomatic BPH, and its ﬁndings will assist pri-
mary care physicians when making treatment deci-
sions.
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